Silent myocardial ischaemia. To screen or not to screen? That is..

Archives of Cardiovascular Diseases

Volumn 101, Issue 9, 2008, Pages 509-511

  Valensi, Paul ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG INDICATION; EARLY DIAGNOSIS; EDITORIAL; GERIATRIC PATIENT; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; PREVALENCE; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; SILENT MYOCARDIAL ISCHEMIA;

EID: 57849110938     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.10.001     Document Type: Article

References (18)

1. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-7.
2. Cosson E, Attali JR, Valensi P. Markers for silent myocardial ischemia in diabetes. Are they helpful? Diabetes Metab 2005;31:205-13.
3. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 2003;26: 1313-4.
4. Valensi P, Paries J, Brulport-Cerisier V, et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a french multicenter study. Diabetes Care 2005;28:2722-7.
5. Bax JJ, Bonow RO, Tschope D, Inzucchi SE, Barrett E. The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2006;48:754-60.
6. Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective? J Am Coll Cardiol 2007;49:1918-23.
7. Miller TD, Redberg RF, Wackers FJ. Screening asymptomatic diabetic patients for coronary artery disease: why not? J Am Coll Cardiol 2006;48:761-4.
8. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
9. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
10. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
12. Pyorala K, Lehto S, De Bacquer D, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia 2004;47:1257-65.
13. Gerstein NC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Action to control cardiovascular risk in diabetes study group. N Engl J Med 2008;358:2545-59.
14. Barthelemy O, Jacqueminet S, Rouzet F, Isnard R, Bouzamondo A, Le Guludec D, et al. Intensive cardiovascular risk factors therapy and prevalence of silent myocardial ischaemia in patients with type 2 diabetes. Arch Cardio Med 2008;101, in this issue.
15. Le Feuvre C, Barthélémy O, Dubois-Laforgue D, Maunoury C, Mogenet, Baubion N, et al. Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with type 2 diabetes. Diabetes Metab 2005;31:135-42.
16. Cosson E, Nguyen MT, Balta C, Pariès J, Valensi P. Intérêt des recommandations Alfediam-SFC sélectionnant les diabétiques gra risque d'ischémie myocardique silencieuse. Une étude de suivi avec analyse des changements de pratique depuis 1992. Diabetes Metab 2008; 34 (special issue):26. (Abstract).
17. Faglia E, Manuela M, Antonella Q, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 2005;149:e1-6.
18. Puel J, Valensi P, Vanzetto G, et al. Identifying myocardial ischaemia in diabetics. SFC/ALFEDIAM joint recommendations. Arch Mal Coeur Vaiss 2004;97:338-57.